These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25482255)

  • 21. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
    Ebers GC; Traboulsee A; Li D; Langdon D; Reder AT; Goodin DS; Bogumil T; Beckmann K; Wolf C; Konieczny A;
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
    Polman CH; Bertolotto A; Deisenhammer F; Giovannoni G; Hartung HP; Hemmer B; Killestein J; McFarland HF; Oger J; Pachner AR; Petkau J; Reder AT; Reingold SC; Schellekens H; Sørensen PS
    Lancet Neurol; 2010 Jul; 9(7):740-50. PubMed ID: 20610349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
    Jesić A; Stefanović D; Delibasić N; Semnic M; Sakallasz L; Dobrenov D; Zivanović Z; Rabi-Zikić T; Zikić M
    Acta Clin Croat; 2009 Jun; 48(2):183-6. PubMed ID: 19928420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
    Kieseier BC
    Expert Rev Neurother; 2014 Jan; 14(1):105-20. PubMed ID: 24417500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
    Bayas A; Gold R
    J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
    Cunningham A; Gottberg K; von Koch L; Hillert J
    Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
    Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
    Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
    Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
    Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
    Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.